Physician profile
Yasser A Khaled
NPI 1023194982
$444,280.90
in general payments reported to CMS, 2019-2025
23 companies · $50K in 2025
The $50K reported for 2025 was more than what 95% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $18K · 2021: $23K · 2022: $101K · 2023: $132K · 2024: $57K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $183K · Consulting Fee: $31K · Travel and Lodging: $14K · Food and Beverage: $5,687 · Honoraria: $5,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $183,295.00 |
| Consulting Fee | $30,660.00 |
| Travel and Lodging | $13,610.08 |
| Food and Beverage | $5,687.17 |
| Honoraria | $5,480.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $113,015.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $85,027.82 | 2022-2025 | Onureg, Breyanzi, Reblozyl |
| Kite Pharma, INC. | $81,465.40 | 2019-2024 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $31,862.45 | 2019-2022 | |
| Seagen INC. | $27,243.32 | 2019-2020 | |
| Amgen INC. | $24,148.34 | 2019-2025 | Blincyto, Blincyto |
| Rigel Pharmaceuticals, INC. | $22,458.97 | 2023-2024 | Rezlidhia, Tavalisse |
| Glaxosmithkline, LLC. | $20,591.95 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $17,887.10 | 2021-2024 | Clonoseq |
| Celgene Corporation | $13,479.01 | 2019-2025 | Breyanzi, Abecma, Onureg |
| Genzyme Corporation | $4,094.84 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $848.23 | 2021-2025 | |
| Astellas Pharma US INC | $446.60 | 2020-2024 | Xospata |
| Janssen Biotech, INC. | $419.10 | 2024-2025 | Carvykti, Rybrevant |
| Incyte Corporation | $377.24 | 2023-2025 | Jakafi, Niktimvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $265.09 | 2024-2025 | Carvykti |
| Sanofi-Aventis U.S. LLC | $205.94 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $158.86 | 2019 | |
| Servier Pharmaceuticals LLC | $121.68 | 2019 | |
| La Jolla Pharmaceutical Company | $112.00 | 2023 | Xerava |
| Autolus INC | $30.80 | 2025 | |
| Pfizer INC. | $20.67 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasser Khaled listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.